Open AccessTK gene combined with mIL-2 and mGM-CSF genes in treatment of gastric cancer
Author(s) -
Shanyu Guo,
Qinxuan Gu,
Zhenggang Zhu,
HsiangHsi Hong,
Yuxin Lin
Publication year - 2003
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v9.i2.233
Subject(s) - suicide gene , transfection , genetic enhancement , cancer , viral vector , cancer research , thymidine kinase , in vivo , cancer cell , ganciclovir , microbiology and biotechnology , bystander effect , gene delivery , biology , medicine , immunology , gene , virus , human cytomegalovirus , biochemistry , herpes simplex virus , recombinant dna
Cancer gene therapy has received more and more attentions in the recent decade. Various systems of gene therapy for cancer have been developed. One of the most promising choices is the suicide gene. The product of thymidine kinase (TK) gene can convert ganciclovir (GCV) to phosphorylated GCV, which inhibits the synthesis of cell DNA, and then induces the cells to death. Cytokines play an important role in anti-tumor immunity. This experiment was designed to combine the TK gene and mIL-2/mGM-CSF genes to treat gastric cancer, and was expected to produce a marked anti-tumor effect.